Skip Navigation
Skip Website Tools

Contact Info

Albert Z. Kapikian, M.D.
Building 50, Room 6306
50 South Drive
Bethesda, MD 20892-8026
Phone: 301-496-3371
Fax: 301-496-8312
akapikian@niaid.nih.gov

Research Feature

Transmission electron micrograph image of rotavirus particles

NIAID researchers and colleagues are pursuing a safer, more effective rotavirus vaccine regimen.

Laboratory of Infectious Diseases

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Albert Z. Kapikian, M.D.

photo of Albert Kapikain

Chief, Epidemiology Section, LID

Major Areas of Research

  • Viral gastroenteritis
  • Vaccine development
  • Electron microscopy
  • Epidemiology
 

Program Description

The Epidemiology Section is concerned with the conception, organization, and implementation of original investigations on the etiology, natural history, epidemiology, immunity, and molecular biology of viral gastroenteritis agents. The section, in addition, has as a mission the development of successful strategies for preventing viral diarrhea.

Specific areas of interest include: development of a rotavirus vaccine for infants and young children; clinical trials of safety, immunogenicity, and protective efficacy of rotavirus vaccine candidates; epidemiology of Norwalk and Norwalk-like viruses in various population groups; and immune electron microscopic studies as a method for detection, identification, and characterization of fastidious agents of viral gastroenteritis and other illnesses, as applicable.

Biography

Dr. Kapikian received his M.D. from Weill Medical College of Cornell University (formerly Cornell University Medical College) in 1956.

Memberships

  • American Epidemiological Society
  • Infectious Diseases Society of America
  • American Society for Virology
  • American Society for Microbiology
  • American Association for the Advancement of Science
  • American Public Health Association
  • Pan American Society for Clinical Virology

Research Group

Lauren A. Rackoff, B.A

Selected Publications

Boon D, Mahar JE, Abente EJ, Kirkwood CD, Purcell RH, Kapikian AZ, Green KY, Bok K. Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. J Virol. 2011 Sep;85(17):8656-66.

Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, Engle R, Yu C, Kapikian AZ, Sosnovtsev SV, Purcell RH, Green KY. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):325-30.

Yuan L, Honma S, Kim I, Kapikian AZ, Hoshino Y. Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4. J Infect Dis. 2009 Nov 1;200(9):1443-51.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis. 2006 Aug 1;194(3):370-6.

Vesikari T, Karvovnen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Neonatal administration of rhesus rotavirus tetravalent vaccine. Ped Infect Dis J. 2006 Feb;25(2):118-22.

Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis. 2005 Sep 1;192 Suppl 1:S22-9.

Visit PubMed for a complete publication listing.

back to top

Patents

Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR, inventors; The United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Hexavalent bovine rotavirus reassortant composition designed for use in developing countries. United States patent US 8,168,202. 1 May 2012.

Kapikian AZ, Chanock RM, Hoshino Y, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Multivalent human-bovine rotavirus vaccine. United States patent US 7,932,074. 26 Apr 2011.

Kapikian AZ, Chanock R, Vesikari T, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions. United States patent US 7,431,931. 7 Oct 2008.

Hoshino Y, Kapikian AZ, Chanock RM, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Attenuated human rotavirus vaccine. United States patent US 7,150,984. 19 Dec 2006.

Potash L, Chanock RM, Purcell RH, Kapikian AZ, inventors; Dyncorp, National Institutes of Health, assignees. Method for producing an adapted virus population from an African green monkey kidney cell line. United States patent US 6,117,667. 12 Sep 2000.

Potash L, Chanock RM, Purcell RH, Kapikian AZ, inventors; Dyncorp, National Institutes of Health, assignees. Method for producing a virus from an African green monkey kidney cell line. United States patent US 6,025,182. 15 Feb 2000.

Visit the U.S. Patent and Trademark Office for a complete patent listing.

back to top

Last Updated July 18, 2013